Congress orders FTC to investigate PBM pricing tactics and report back

What it does

This bill directs the Federal Trade Commission to study how pharmacy benefit managers (PBMs) and other intermediaries operate in the drug supply chain, with a focus on whether they engage in anticompetitive practices like steering patients to their own pharmacies, using proprietary data unfairly, or manipulating drug formularies to favor expensive medications. The FTC must report back to Congress within one year with findings and policy recommendations to improve transparency and competition, plus a separate interim report at 180 days.

Why we flagged it

The bill's operative mechanism is a mandated FTC study and report on PBM and intermediary conduct, with a focus on anticompetitive practices and policy recommendations. It is not a direct regulatory change or enforcement action, but rather a fact-finding and recommendation instrument.

What the text implies

• The study may expose PBM self-dealing (e.g., steering to owned pharmacies, using proprietary data for competitive advantage) that could trigger future FTC enforcement actions or congressional legislation restricting PBM practices.
• A finding that PBMs manipulate formularies to favor higher-cost drugs could undermine the industry's claim that rebates and discounts offset price increases, potentially shifting political pressure toward direct price regulation.

The full analysis lists 4 implications of this text.

Who it affects

The bill creates transparency and investigative pressure on an opaque, concentrated industry (PBMs) that directly affects drug prices and patient access. Citizens benefit from a formal FTC study that may expose anticompetitive practices and lead to enforcement or legislative remedies; there are no direct costs to the public, and the study mechanism itself does not shield any party from liability.